Goldman Sachs is leading a record surge of US banks borrowing in renminbi. The idea is simple: use China’s record-low borrowing costs to cheaply fund global operations. 1/
For decades the yen played this role but as Japanese rates have normalised the renminbi is filling the gap. The activity is boosting the renminbi's role in global finance at a time when more countries and investors are questioning the role of the dollar. 2/
Michael Burry's series on the HK market is a good read.
"The largest Hong Kong companies are widely known and poorly understood. These stocks have had 1929-style crashes while the businesses kept growing."
Check it out: https://t.co/yAH4qxlm0f
Few people recognise how embedded Chinese businesses are in AI supply chains. But investors do! And they are betting Chinese battery and energy storage system companies will be the main game in town for the frenzied global AI buildout.
As rupee falls below the 90/$ threshold today, some facts about the booming equity markets: India has underperformed compared to its peers with the widest gap in 30 years. @wtbs_@christopherkay@haohsiang0509@FT
https://t.co/qZ6uMSVSPt
External renminbi loans, deposits and bond investments by Chinese banks quadrupled to more than Rmb3.4tn ($480bn) over the past five years, as Beijing steps up efforts to expand the currency’s role in global finance and reduce exposure to the US dollar https://t.co/UlY6eCg3Yo
The rise of DeepSeek has rekindled interest in China's innovative small businesses — known as 小巨人, or "little giants" — developing technology that can drive future economic growth. Beijing's little-known stock exchange is becoming an IPO hub for these small tech companies. The businesses listed there make everything from data centre cooling equipment and battery materials to the carbon fibre used in aircraft and satellites.
Biotech companies from mainland China are pushing boundaries in fundamental cancer research and investors are taking notice. The Hang Seng Biotech index is up over 60% this year, with companies like 3SBio Inc. and Akeso Biopharma leading gains as they sign licensing agreements with western pharmaceutical groups for new drugs that have the potential to transform how we treat cancer.
Taiwan's central bank has warned foreign investors against violating its capital controls. The warning comes as it seeks to rein in the New Taiwan dollar’s sharp rally without being labelled a currency manipulator by the US.
“In China every yield is going down except for the dividend yield.”
China's big banks have become bond proxies as investors hunt for yield at a time of record-low interest rates. The country's insurance industry is helping drive the trend.